Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06303583
PHASE1/PHASE2

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

Sponsor: Qiu Guoqin

View on ClinicalTrials.gov

Summary

The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2022-06-01

Completion Date

2026-12-31

Last Updated

2024-03-12

Healthy Volunteers

No

Interventions

DRUG

paclitaxel

paclitaxel, 50 mg/m2, QW\*5

DRUG

carboplatin

area under the curve of2mg/mL/min, QW\*5

DRUG

tislelizumab

200mg Q3W, 2cycles

RADIATION

radiotherapy

41.4Gy in 23 fractions

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China